|
|
||||||||
The Annals of Thoracic Surgery, Vol 49, 927-930, Copyright © 1990 by The Society of Thoracic Surgeons
CD Stone, BR Rosengard, SM Boorstein, RC Robbins, HA Hennein and RE Clark
Prostaglandin E2 (PGE2) has been shown to a clear role in the suppression
of immune responses after burn and trauma injury. This probably results
from inhibition of interleukin-2 production. This study examined the
effects of PGE2 in vivo on the survival of solid- organ allografts and in
vitro on the rat allogeneic mixed lymphocyte response. Administration of
16,16-dimethyl prostaglandin E2 (DMPGE2), a stable analogue of PGE2,
significantly prolonged the survival of heterotopic cardiac allografts from
ACI to LBN rats: 10.4 +/- 1.7 days versus 5.7 +/- 1.1 days (mean +/-
standard error of the mean) (p less than or equal to 0.001). In 1 animal,
DMPGE2 apparently led to the induction of long-term tolerance. Mixed
lymphocyte cultures using splenocytes from naive LBN and ACI rats to which
DMPGE2 was added showed a dose-dependent suppression of the mixed
lymphocyte response with concentrations as low as 1 x 10(-7) mol/L.
Splenocytes harvested from treated animals with functioning but
histologically rejecting hearts demonstrated a marked decrease in mixed
lymphocyte response to donor (ACI) stimulators compared with naive LBN
controls (3,804 +/- 603 versus 27,395 +/- 2,668 cpm, n = 4), but maintained
a normal response to third-party (Wistar Furth) stimulators. We conclude
that DMPGE2 suppressed solid-organ allograft rejection, inhibited the
allogeneic mixed lymphocyte response, and induced donor-specific in vitro
hyporesponsiveness.
ARTICLES
Prostaglandin E2 inhibits in vitro and in vivo lymphocyte responses in allogeneic transplantation
Surgery Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.
This article has been cited by other articles:
![]() |
T. Yokoyama, O. Aramaki, T. Takayama, S. Takano, Q. Zhang, M. Shimazu, M. Kitajima, Y. Ikeda, N. Shirasugi, and M. Niimi Selective cyclooxygenase 2 inhibitor induces indefinite survival of fully allogeneic cardiac grafts and generates CD4+ regulatory cells J. Thorac. Cardiovasc. Surg., October 1, 2005; 130(4): 1167 - 1174. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |